MIM
CRDF icon

MetLife Investment Management’s Cardiff Oncology CRDF Stock Holding History

MetLife Investment Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,230
Closed -$17.5K – 2783
2025
Q4 		$17.5K Buy
+6,230
New +$14.5K ﹤0.01% 2788
2025
Q3 		– Sell
-36,363
Closed -$115K – 2858
2025
Q2 		$115K Buy
36,363
+637
+2% +$1.94K ﹤0.01% 2469
2025
Q1 		$112K Buy
35,726
+9,167
+35% +$36.3K ﹤0.01% 2473
2024
Q4 		$115K Buy
+26,559
New +$83K ﹤0.01% 2561
2021
Q4 		– Sell
-14,624
Closed -$97.4K – 2507
2021
Q3 		$97.4K Buy
+14,624
New +$91.9K ﹤0.01% 2451

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

MetLife Investment Management's CRDF Position: Q1 2026 in Review

MetLife Investment Management sold out of Cardiff Oncology (CRDF) in Q1 2026, closing a stake of 6,230 shares — an estimated $17.5K sold.

MetLife Investment Management first reported a position in CRDF in Q3 2021 and held it in 5 quarters. The position peaked at $115K in Q4 2024. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • MetLife Investment Management reported no remaining Cardiff Oncology position as of Q1 2026 after selling out during the quarter.
  • MetLife Investment Management sold 6,230 Cardiff Oncology shares in Q1 2026, an estimated $17.5K.
  • MetLife Investment Management first reported a position in Cardiff Oncology in Q3 2021 and held it in 5 quarters.
  • MetLife Investment Management's Cardiff Oncology position peaked at $115K in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.